IL1B and familial Mediterranean fever: The objective of this study was to evaluate the efficacy and safety of canakinumab, a fully human anti-IL-1β monoclonal antibody with a half-life of approximately 4 weeks, that binds to human IL-1β and neutralizes its proinflammatory effects, in adolescent and adult patients with FMF, who are resistant or intolerant to higher doses of colchicine.